Neuro sale

Quote






"For the past year, the company had indicated its desire to divest or cease the proprietary products business, though, the quantum received through the divestitures (~$170 mn) is significantly shy of the US$650-700 mn spent on developing the products from FY2013-19. Given our long-standing concerns over the scalability of DRRD's proprietary products strategy and questionable product selection track record, we believe the divestitures are a correct step,"

The above lines in the report reveal what morons have been doing all these years: questionable product selection, developing products that couldn't recoup even a third of invested dollars, and finally the incompetence of Indian management who allowed a bunch of money-raiders and kool-aid drinkers to keep siphoning off money in return of selling dreams, and once they were gone, close down entire business. Now, q is, what DRL is banking on for the future growth: biosimilars..again a generic play. From what Mr. Israeli says, its obvious, specialty business of DRL is CLOSED!

"Maybe there was a perception in the past that we are becoming from a generic company to a specialty company. This is not the case. We are generic company and will stay generic company in that respect. May be here and there we will have a nice asset in specialty that can serve us well. In that respect, the main effort will be, if at all, complementary moves in the generic area," Israeli clarified.
 






















































Top Bottom
Back
Quote